Use cautiously in patients with hyperthyroidism, hypertension and cardiac arrhythmias Side Effects: Transient and minor side effects of: Anxiety Tachycardia Headache Fear and palpitations occur with systemic therapeutic doses Adverse effects such as cardiac arrhythmias and excessive rise in blood pressure may also occur with therapeutic doses or inadvertent overdosage Side effects are more likely to be observed in hyperthyroid individuals Pharmacokinetics: Route of administration depends on the indication for its use : i.v., s.c., i.m., intranasal, via an endotracheal tube, or direct injection into the left ventricle
More recently, encouraging clinical results from a triple-hormone-receptor agonist, Retatrutide, and several GLP-1R/GCGR dual agonists, suggest that GCGR could be a promising co-stimulating target for type 2 diabetes and obesity
TRZ was approved in 2022 for the treatment of T2D and obesity, mainly in patients with cardio-metabolic disorders (Boutari et al
49 GLP-1RA is primarily used for the treatment of T2DM 68 and works by mimicking the action of the naturally occurring hormone GLP-1, which is released by the intestines in response to food intake
It is useful to think of in pharmacological dose-response terminology as the EC 50 of this GSH-glucose relationship
